AMAG Pharma (AMAG) Posts Q3 Loss of $1.29
More News related to AMAG
- AMAG Pharmaceuticals, Inc. to Participate in the Lazard Capital Markets 6th Annual Healthcare Conference
- Baird Reiterates an 'Outperform' on AMAG Pharmaceuticals (AMAG); Incrementally Positive on CMS News
- AMAG Pharma (AMAG) Posts Q3 Loss of $1.29
- AMAG Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2009
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
More News related to Earnings
- Longbow Research Initiates Coverage on Landstar System (Nasdaq: LSTR) with a Neutral
- ThinkEquity Initiates Coverage on Allos Therapeutics (ALTH) with a Buy
- Credit Suisse Resumes Coverage on Brookfield Infrastructure Partners L.P. (BIP) with a Neutral
- Fox-Pitt Initiates Coverage on Community Bank System (CBU) with an 'In-Line' Rating
- Keefe, Bruyette & Woods initiates coverage on Apartment REITs: AEC, AIV, CPT, EQR, ESS, HME, PPS and UDR
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) reports Q3 loss of $1.29, versus the analyst estimate of ($1.47). Revenue for the quarter was $ million, which compares to the estimate of $3.04 million.
Related Categories
EarningsStocks Mentioned
+0.29Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
